Pericardial involvement during the course of XXXX . A long-term clinical and echocardiographic study.

@entity1 @entity1143 @entity712 @entity2293 @entity2294 @entity2396 @entity1188 @entity583 @entity204
STUDY OBJECTIVE: This study investigated the long-term course of @entity1188 and @entity2294 . Focus was given to the following issues: incidence and timing of @entity2396 and @entity2294 during the acute phase and 3 years follow-up, size, hemodynamic and clinical consequences of effusions, and potential risk of thrombolytic or anticoagulant therapy in @entity1 with @entity2294 . @entity1 AND STUDY DESIGN: Serial echocardiographic examinations were performed in 192 consecutive @entity1 with first @entity583 during the acute phase (day 1, 5, 10, 21) and during 3 years' follow-up (year 1, 2, and 3 after @entity1188 ). The follow-up was 100%. Clinical, angiographic, and autopsy data were analyzed. RESULTS: Pericardial @entity1143 was detected at least once during serial echocardiographic examinations in 82 of 192 @entity1 (43%). The incidence in different subgroups (with or without thrombolysis, open or closed artery at 3 weeks, @entity1188 in left anterior descending, left circumflex, or right coronary artery perfusion bed) was similar. Most (48%) effusions were first detected on the fifth day, and most (50%) disappeared between days 21 and 365. However, in nine @entity1 , the @entity1143 persisted beyond 1 year (up to 3 years in three @entity1 ). Only systolic separation of pericardial layers was detected in 59% of effusions, circular @entity1143 in 3.6% of all effusions. No @entity2293 developed. @entity712 or @entity204 complicated 49% of @entity1188 with pericardial involvement and 16% of @entity1188 without @entity1143 (p < 0.01). Mortality alone was 8% among @entity1 without @entity1143 and 15% among those with more than minimal @entity1143 (not significant). CONCLUSIONS: Pericardial @entity1143 can be detected by serial echocardiographic examinations in 43% of @entity583 . It appears during the initial 5 days and disappears slowly during several weeks to several months. Anticoagulant and thrombolytic therapy does not increase the frequency or the size of effusions.
